Liu, P., Li, Z., Cen, H., Jin, Z., Zang, A., Sun, X., Gao, S., Cao, J., Zhang, Q., Li, Y., Lai, X., Wang, J., Li, F., Yang, S., Qian, W., Wang, H., Tang, X., Ding, L., Zhou, H., Shi, Y. (2025). Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7007